✦ LIBER ✦

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer

✍ Scribed by Rupert Bartsch; Zsuzsanna Bago-Horvath; Anna Berghoff; Catharina DeVries; Ursula Pluschnig; Peter Dubsky; Margaretha Rudas; Robert M. Mader; Andrea Rottenfusser; Florian Fitzal; Michael Gnant; Christoph C. Zielinski; Guenther G. Steger

Book ID: 116431087
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 302 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.03.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

45 Ovarian Function Suppression Plus Ful

45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer

✍ R. Bartsch; Z. Bago-Horvath; U. Pluschnig; A. Berghoff; P. Dubsky; R.M. Mader; F 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 65 KB

An individual patient-based meta-analysi

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

✍ Michael Crump; Carol A. Sawka; Gerrit DeBoer; Roger B. Buchanan; James N. Ingle; 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 61 KB

Fulvestrant in postmenopausal women with

Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy — results from an expanded access programme

✍ L Petruzelka; M Zimovjanova 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 332 KB

Fulvestrant in postmenopausal women with

Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy-updated results from an expanded access programme

✍ L. Petruzelka; Konopasek; O. Pribylova; P. Mares; M. Zimovjanova 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Combined endocrine effects of LHRH agoni

Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer

✍ Mr J. F. R. Robertson; K. J. Walker; R. I. Nicholson; R. W. Blamey 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 2 views

Abstract In premenopausal women with breast cancer, the use of the luteinizing hormone releasing hormone agonist, goserelin, results in the production of serum levels of oestradiol equivalent to those after surgical oöphorectomy or in postmenopausal women. The standard first line hormonal treatment

P315 Acceptance and adherence with oral

P315 Acceptance and adherence with oral endocrine therapy in women with metastatic breast cancer: ExaCampania group study

✍ R. Addeo; P. Russo; L. Maiorino; A. Febraro; L. Leo; P. Incoronato; A. Pisano; M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB